JAZZ250117P130000
- 7.31
- -0.20-2.66%
Jazz Pharmaceuticals Newsroom
Executive Reshuffles: BA, EXPE, TPVG and GEO
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Cuts Target Price to $195
TD Cowen Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $195
Jazz Pharmaceuticals (JAZZ) Gets a Buy From TD Cowen
Jazz Pharmaceuticals Announces CEO Succession Plan; Bruce Cozadd, Co-Founder, Chairperson And CEO, Plans To Retire As CEO Upon Appointment Of Successor By The End Of 2025; Will Continue As Chair Of The Board; Jazz Remains On Track To Meet Its FY24...
Express News | Jazz Pharmaceuticals PLC: Bruce Cozadd Will Continue as Chair of Board
Express News | Jazz Pharmaceuticals Outlook FY Revenue USD 4,000-4,100 Million
Express News | Jazz Pharmaceuticals Announces CEO Succession Plan
Press Release: Jazz Pharmaceuticals Announces CEO Succession Plan
Sentiment Still Eluding Jazz Pharmaceuticals Plc (NASDAQ:JAZZ)
Analysts Conflicted on These Healthcare Names: Jazz Pharmaceuticals (JAZZ), Acadia Healthcare (ACHC) and Genmab (GMAB)
Express News | Jazz Pharmaceuticals PLC : Truist Securities Raises Target Price to $220 From $200
Is Now The Time To Put Jazz Pharmaceuticals (NASDAQ:JAZZ) On Your Watchlist?
Truist Financial Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating
A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $163 to $230
Top Gap Ups and Downs on Thursday: CIEN, WBD, ADBE and More
Morgan Stanley Upgrades Jazz Pharmaceuticals to Overweight From Equalweight, $175 Price Target
Piper Sandler Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $163
Piper Sandler Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)